R&D Information Center: Analysis of Next-Generation Vaccine and Innovative Drug Development Platform Technologies and R&D Trends

The nature of this document is now more intense than ever before in the era of social distance change, with Corona19 fandeminics sweeping the world in recent times. To counter the Corona19s, each country has applied a variety of vaccine platforms developed, and as a result, the period of vaccine development has been reduced dramatically against the traditional infectious diseases. There was a problem that earlier had been very slow in developing vaccines, and that the recent viral infection, including corona 19, took place in the short term, and therefore required rapid development of vaccines. The successful application of the MRA vaccine platform in Corona19 is being rated as a significant achievement in the history of human vaccine development. The development of the drug, based on a high level of scientific research, requires long-term development and high-exploited development costs, as well as very high rates of failure at each stage, which is so uncertain. However, the latest high-tech, highly competitive technology has been using the drug development age and cost to a marked extent. Biotech and pharmaceutical companies are on the rise in the development of drug drugs to improve production, and with AI technology, drug development periods are reported to be reduced from 10 to 3 years, and the cost of retail costs from $1.20 billion to 60 billion. In addition, high-tech research has been taking advantage of the development of drugs, such as Autonoids, the most fully-immune microscopes, and Big Data.

Korean title: 차세대 백신 및 혁신신약 개발 플랫폼 기술과 R&D 동향 분석

Korean author: R&D정보센터

Korean publisher: 지식산업정보원

ISBN-13: 9791158621940